Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) studie

24. september 2026 oppdatert av: Zimmer Biomet

Prospektiv postmarkedsklinisk oppfølgingsstudie av kontinuummetallet på polyetylen acetabulært system

This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.

Studieoversikt

Detaljert beskrivelse

The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.

Studietype

Observasjonsmessig

Registrering (Faktiske)

195

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Fremont, California, Forente stater, 94538
        • Sah Orthopaedic Associates
    • Colorado
      • Denver, Colorado, Forente stater, 80204
        • Denver Health Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients from surgeons medical practice who are candidates for primary hip arthroplasty.

The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.

Beskrivelse

Inclusion Criteria

  • Patient is 18 to 75 years of age, inclusive.

  • Patient is skeletally mature.

  • Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:

    • Avascular necrosis (AVN)
    • Osteoarthritis
    • Inflammatory arthritis (i.e., Rheumatoid arthritis)
    • Post-traumatic arthritis
  • Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).

  • Patient has moderate, marked or disabling pain.

  • Patient is willing and able to provide written informed consent.

  • Patient is willing and able to cooperate in the required post-operative therapy.

  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.

  • Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.

Exclusion Criteria:

  • The patient is:

    • A prisoner
    • Mentally incompetent or unable to understand what participation in the study entails
    • A known alcohol or drug abuser
    • Anticipated to be non-compliant
  • The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.

  • The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.

  • The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.

  • The patient is known to be pregnant.

  • The patient is unwilling or unable to give consent or to comply with the follow-up program.

  • The patient has received an investigational drug or device within the previous 6 months.

  • The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.

  • The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.

  • The patient has osteoradionecrosis in the affected hip joint.

  • The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.

  • The patient has known local bone tumors and/or cysts in the operative hip.

  • The patient has a Body Mass Index (BMI) > 40.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Continuum Acetabular System

Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System

Used in primary hip arthroplasty

Andre navn:
  • Total hofteprotese, total hofteprotese, primær hofte

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Survivorship
Tidsramme: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Safety / Adverse Events
Tidsramme: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.

Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain and Function / HHS
Tidsramme: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Pain and function will be measured using the Harris Hip Score self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Pain and Function / OHS
Tidsramme: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Pain and function will be measured using the Oxford Hip Score self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Health Status / SF-12
Tidsramme: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Health status will be measured using the SF-12 self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Health Status / Radiographic Parameters
Tidsramme: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Metal Ion / Cobalt
Tidsramme: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Metal Ion / Chromium
Tidsramme: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Metal Ion / Titanium
Tidsramme: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / BUN
Tidsramme: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / Creatinine
Tidsramme: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / GFR
Tidsramme: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Hillary Overholser, Zimmer Biomet

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mars 2011

Primær fullføring (Faktiske)

17. juli 2026

Studiet fullført (Faktiske)

17. juli 2026

Datoer for studieregistrering

Først innsendt

25. februar 2011

Først innsendt som oppfylte QC-kriteriene

28. februar 2011

Først lagt ut (Antatt)

2. mars 2011

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere